Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: Reversal with antihypertensive agents and effect on tumor growth inhibition

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 3, 2009, Pages 928-937

  Franklin, Pamela H ^a   Banfor, Patricia N ^a   Tapang, Paul ^a   Segreti, Jason A ^a   Widomski, Deborah L ^a   Larson, Kelly J ^a   Noonan, William T ^a   Gintant, Gary A ^a   Davidsen, Steven K ^a   Albert, Daniel H ^a   Fryer, Ryan M ^a   Cox, Bryan F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AMLODIPINE; ENALAPRIL; EPROSARTAN; LISINOPRIL; NIFEDIPINE; RAMIPRIL; TELMISARTAN;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HYPERTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCID MOUSE; SPRAGUE DAWLEY RAT; TELEMETRY;

ACRYLATES; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HUMANS; IMIDAZOLES; INDAZOLES; LISINOPRIL; MALE; MICE; MICE, SCID; NEOPLASMS; NIFEDIPINE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; THIOPHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66749173111     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.144816     Document Type: Article

References (27)

1. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, et al. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006. (Pubitemid 43724600)
2. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, and Yeo CJ (2007) Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204:996-1005; discussion 1005-1006. (Pubitemid 46661215)
3. Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, and Sotelo J (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247-1252. (Pubitemid 40604399)
4. Battegay EJ, de Miguel LS, Petrimpol M, and Humar R (2007) Effects of antihypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 7:151-157. (Pubitemid 46404741)
5. Blume-Jensen P and Hunter T (2001) Oncogenic kinase signalling. Nature 411:355-365. (Pubitemid 32467045)
6. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, and Wedge SR (2008) Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 14:3124-3131.
7. Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, et al. (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584-1597. (Pubitemid 46564379)
8. Dincer M and Altundag K (2006) Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 40:2278-2279. (Pubitemid 44954457)
9. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, et al. (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67-75. (Pubitemid 38056377)
10. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35. (Pubitemid 46630490)
11. Fujita M, Hayashi I, Yamashina S, Itoman M, and Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441-447. (Pubitemid 34694114)
12. Goh BC, Thng CH, Sukri N, Wong CI, Soo R, Carr R, Lee SC, Chen CS, and Humerickhouse R (2006) Phase I study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Eur J Cancer Suppl 4:1.
13. Gschwind A, Fischer OM, and Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-370. (Pubitemid 38579482)
14. Herbst RS (2006) Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 8 (Suppl 1:S23-S30.
15. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844. (Pubitemid 23132159)
16. Lin MI and Sessa WC (2006) Vascular endothelial growth factor signaling to endothelial nitric oxide synthase: more than a FLeeTing moment. Circ Res 99:666-668. (Pubitemid 44498299)
17. Millauer B, Shawver LK, Plate KH, Risau W, and Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579. (Pubitemid 2027191)
18. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, and Hayakawa M (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176-4179. (Pubitemid 34830392)
19. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, and Sotelo J (2001) AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85:1396-1399. (Pubitemid 33081938)
20. Schenone S, Bondavalli F, and Botta M (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 14:2495-2516. (Pubitemid 47618038)
21. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, et al. (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206. (Pubitemid 46631363)
22. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, et al. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109:3400-3408. (Pubitemid 46572529)
23. Tomayko MM and Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154. (Pubitemid 19163397)
24. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, and Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073-1078. (Pubitemid 32708747)
25. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424. (Pubitemid 28197463)
26. Zhou J, Khng J, Jasinghe VJ, Bi C, Neo CH, Pan M, Poon LF, Xie Z, Yu H, Yeoh AE, et al. (2008a) In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res 32:1091-1100.
27. Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, et al. (2008b) Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22:138-146.